DIVIS LABORATORIES Surges by 5%; BSE HEALTHCARE Index Down 0.1%
February 4, 2019 11 am

DIVIS LABORATORIES share price has zoomed 5% and is presently trading at Rs 1,609.

Meanwhile, the BSE HEALTHCARE Index is at 14,037 (down 0.1%).

Among the top Gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 5.1%) and BLISS GVS PHARMA (up 5.5%).

FORTIS HEALTHCARE (down 0.1%) and AJANTA PHARMA (down 0.2%) are among the top losers today.

Over the last one year, DIVIS LABORATORIES has moved up from Rs 1,041 to Rs 1,609, registering a gain of Rs 568 (up 54.6%).

On the other hand, the BSE HEALTHCARE has moved down from 14,359 to 14,037, loss of 322 points (down 2.6%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were DIVIS LABORATORIES (up 54.6%), ABBOTT INDIA (up 46.7%) and TORRENT PHARMA (up 35.7%).

What About the Benchmark Indices?

The BSE Sensex is at 36,456 (down 0.4%).

The top gainers among the BSE Sensex stocks today are ONGC (up 1.4%), BAJAJ AUTO (up 1.1%) and RELIANCE IND. (up 0.9%). Other gainers include HUL (up 0.9%) and HCL TECH. (up 0.5%). The most traded stocks in the BSE Sensex are TATA MOTORS and ONGC.

In the meantime, NSE Nifty is at 10,879 (down 0.4%). TITAN COMPANY (up 4.6%) and EICHER MOTOR (up 3.0%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved up from 35,907 to 36,456, registering a gain of 549 points (up 1.2%).

DIVIS LABORATORIES Financial Update...

DIVIS LABORATORIES net profit stood at Rs 4 billion for the quarter ended December 2018, compared to a profit of Rs 2 billion a year ago. Net Sales rose 29.4% to Rs 13.4 billion during the period as against Rs 10.4 billion in October-December 2017.

For the year ended March 2018, DIVIS LABORATORIES reported 17.3% decrease in net profit to Rs 8.8 billion compared to net profit of Rs 10.6 billion during FY17.

Revenue of the company grew 4.7% to Rs 39 billion during FY18.

The current Price to earnings ratio of DIVIS LABORATORIES, based on rolling 12 month earnings, stands at 32.7x.